Affiliation: Duke University Medical Center
- Medication taking behaviors among breast cancer patients on adjuvant endocrine therapyGretchen Kimmick
Duke Cancer Institute, Duke University Medical Center, DUMC Box 3204, Durham, NC 27710, USA Electronic address
Breast 24:630-6. 2015..To explore how symptoms and psychosocial factors are related to intentional and unintentional non-adherent medication taking behaviors...
- Hot flashes in breast cancer survivors and an association with calcium supplement useGretchen Kimmick
Medical Oncology, Wake Forest University School of Medicine, Winston Salem
Int J Womens Health 2:291-4. 2010..In breast cancer survivors, we aimed to describe the frequency of hot flashes and night sweats, frequency and type of treatment, and the association of hot flashes and use of calcium supplements...
- Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision makingGretchen Kimmick
Multidisciplinary Breast Program, Duke University Medical Center, Durham, NC 27710, USA
Curr Treat Options Oncol 12:286-301. 2011..In addition, as always in oncology, physicians and patients should look for and participate in clinical trials that will define how to treat cancer, especially in older patients, in the future...
- Adjuvant hormonal therapy use among insured, low-income women with breast cancerGretchen Kimmick
Associate Professor of Medicine, Duke University Medical Center, Box 3204, Suite 3800 Duke South, Durham, NC 27710, USA
J Clin Oncol 27:3445-51. 2009..Improving use of adjuvant hormonal therapy may lead to lower breast cancer-specific mortality in this population...
- Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)G G Kimmick
Duke University Medical Center, Duke South, Durham, NC 27710, USA
Breast Cancer Res Treat 113:479-90. 2009..To describe long-term results of a multimodality strategy for stage III breast cancer utilizing neoadjuvant doxorubicin followed by mastectomy, CMF, and radiotherapy...
- Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifenGretchen G Kimmick
Wake Forest University School of Medicine, Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
Breast J 12:114-22. 2006..Sertraline decreases hot flashes in breast cancer survivors taking tamoxifen and women prefer sertraline to placebo. Further study of sertraline for the management of hot flashes is warranted...
- Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001Gretchen G Kimmick
Duke University Medical Center, Suite 3800 Duke S, Box 3204, Durham, NC 27710, USA
J Clin Oncol 23:2201-7. 2005..To design and test a geriatric educational intervention to improve accrual of cancer patients age 65 years and older to cooperative group-sponsored treatment trials...
- Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapyLee W Jones
Duke Cancer Institute, Duke University Medical Center, Box 3085, Durham, NC 27710, USA
Cancer Prev Res (Phila) 6:925-37. 2013..Data from this exploratory study provide initial evidence that AET can modulate several host- and tumor-related pathways during standard chemotherapy. The biologic and clinical implications remain to be determined...
- Survival disadvantage among Medicaid-insured breast cancer patients treated with breast conserving surgery without radiation therapyKristie Long Foley
Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
Breast Cancer Res Treat 101:207-14. 2007..It is possible that the prognostic significance of omission of RT in clinical trials underestimates the significance of risk in the community...
- Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancerErika Hamilton
Duke Cancer Institute, Durham, NC
Clin Breast Cancer 13:416-20. 2013....
- Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income womenKathryn E Weaver
Department of Social Sciences and Health Policy, Medical Center Boulevard, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
Am J Clin Oncol 36:181-7. 2013..We explored the relationship between adherence to tamoxifen or selective aromatase inhibitors with cancer recurrence and death in a low-income, Medicaid-insured population...
- Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracyIsaac M Lipkus
Duke University School of Nursing, Durham, NC, USA
Med Decis Making 30:464-73. 2010..Results suggest that numeracy influences a patient's ability to interpret numerical estimates of treatment efficacy from decision aids such as Adjuvant!...
- Multidisciplinary care of patients with early-stage breast cancerGary H Lyman
Comparative Effectiveness and Outcomes Research Program, Department of Medicine, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27705, USA
Surg Oncol Clin N Am 22:299-317. 2013..The essential role for coordinated involvement of the entire health care team in optimal management of patients with early-stage breast cancer is likely to increase further...
- Comorbidity burden and guideline-concordant care for breast cancerGretchen Kimmick
Department of Internal Medicine, Division of Oncology, Duke University Medical Center, Durham, North Carolina
J Am Geriatr Soc 62:482-8. 2014..To explore the relationship between level and type of comorbidity and guideline-concordant care for early-stage breast cancer...
- Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041)Gretchen Kimmick
Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC 27157, USA
Invest New Drugs 22:83-9. 2004..Good performance status was the most important predictor of survival. In this group of women with metastatic breast cancer, the overall prognosis was poor. This combination of rIL-2 and IFN was ineffective...
- Breast cancer in older patientsGretchen Kimmick
Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
Semin Oncol 31:234-48. 2004..The goals in treating metastatic breast cancer in an older patient are not different than for younger patients...
- Interpreting measures of treatment effect in cancer clinical trialsL Douglas Case
Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
Oncologist 7:181-7. 2002..The most common mistake is to interpret both measures as relative risks, an interpretation that can lead to an incorrect impression of the impact of the treatment on response and survival...
- A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancerCarey Anders
Division of Medical Oncology, Duke University Department of Medicine, Durham, North Carolina, USA
Cancer Invest 26:286-95. 2008..Premenopausal women treated for early stage breast cancer (ESBC) are at risk for chemotherapy-related amenorrhea (CRA). Prospectively-validated, predictive markers of CRA are needed...
- Patient experience and attitudes toward addressing the cost of breast cancer careBlair Irwin
Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA
Oncologist 19:1135-40. 2014..The American Society of Clinical Oncology views patient-physician discussion of costs as a component of high-quality care. Few data exist on patients' views regarding how cost should be addressed in the clinic...
- BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancerMara Z Vitolins
Division of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
Breast J 14:357-65. 2008....
- Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breastGretchen G Kimmick
The Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC 27157 1082, USA
Breast Cancer Res Treat 72:233-43. 2002..This single-arm study aimed to evaluate the effectiveness of an intensive doxorubicin-based multidrug regimen as adjuvant therapy in women with stage II, node positive breast cancer...